Pharmaceutical Pricing And Reimbursement: Strategies For Market Access Across The Us, Europe, Japan And Other Key Geographies : Market Research Report

Pharmaceutical Pricing And Reimbursement: Strategies For Market Access Across The Us, Europe, Japan And Other Key Geographies

Published: Nov. 1, 2007 - 143 Pages

Pharmaceutical Pricing and Reimbursement
Executive Summary: An introduction to price optimization; Pricing and reimbursement in North America; Pricing and reimbursement in Europe; Pricing and reimbursement in Japan and the rest of the world; Global pricing strategies; Lifecycle pricing strategies
Chapter 1 An introduction to price optimization: Summary; Introduction; Delivering a return on investment; Healthcare cost containment; Key issues impacting on pricing; Global versus lifecycle pricing
Chapter 2 Pricing and reimbursement in North America: Summary; Introduction; US pricing regulations; Recent developments in the US; Future pricing scenarios in the US
Chapter 3 Pricing and reimbursement in Europe: Summary; Introduction; European pricing regulations; French pricing regulations; Recent developments in France; German pricing regulations; Recent developments in Germany; Italian pricing regulations; Recent developments in Italy; Spanish pricing regulations; Recent developments in Spain; UK pricing regulations; Recent developments in the UK
Chapter 4 Pricing and reimbursement in Japan and the rest of the world: Summary; Introduction; Japanese pricing regulations; Recent developments in Japan; Future pricing scenarios in Japan; Australian pricing regulations; Recent developments in Australia; Chinese pricing regulations; Recent developments in China
Chapter 5 Global pricing strategies: Summary; Introduction; Local optimization; Global coordination; Launch sequence; Optimal price differentials; Implementing global pricing strategies
Chapter 6 Lifecycle pricing strategies: Summary; Introduction; Launch phase pricing considerations; Patent protected phase pricing considerations; Patent expiry phase pricing considerations; Implementing lifecycle pricing strategies
Chapter 7 Appendix: Glossary; Sources
List of Figures: Figure 1.1: Declining trend in number of NDA and NME approvals, 1997-2006; Figure 1.2: Rise in the cost of drug development, 1975-2001; Figure 1.3: US patent expiries for top ten selling drugs, 2006-2011; Figure 1.4: Trends in healthcare spending as a proportion of GDP, 1970-2005; Figure 1.5: Pharmaceutical expenditure as a share of total healthcare expenditure in 2005; Figure 2.6: Source of prescription drug expenditures, 2005-2006; Figure 2.7: Canadian cross border internet pharmacy sales, 2002-2006; Figure 2.8: Compensatory final settlements (reverse payments), 2004-2006; Figure 3.9: Average ex-factory drug prices in key European markets, 2005; Figure 4.10: NHI price cuts by therapeutic class, 2006; Figure 5.11: Market share for new products launched in last five years, 2005; Figure 5.12: External reference pricing in Europe, 2007; Figure 5.13: Global pricing and the interaction between countries; Figure 5.14: Global pricing strategies; Figure 6.15: Leading respiratory drugs by global sales, 2006; Figure 6.16: Lifecycle pricing strategies
List of Tables: Table 1.1: Number of NDA and NME approvals by the FDA, 1990-2006; Table 1.2: R&D expenditure within the US and abroad by PhRMA members, 1980-2006; Table 1.3: Trends in healthcare spending as a proportion of GDP, 1970-2005 (%); Table 2.4: Future pricing scenarios in the US; Table 3.5: Future pricing scenarios in Europe; Table 4.6: Co-payments for drugs/services in Japan; Table 4.7: Classification for price premium (Japanese healthcare system); Table 4.8: Future pricing scenarios in Japan

Abstract

The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies. By incorporating such assessments into portfolio evaluations and lifecycle planning, companies can enhance their understanding of potential price profiles for individual drugs and optimise future returns. ‘Pharmaceutical Pricing and Reimbursement’ is a new report published by Business Insights that examines the tactical importance of price optimization throughout the product lifecycle. The key issues affecting pricing and reimbursement disciplines are identified and the market environments of individual countries are assessed. This report will also detail the global and lifecycle pricing strategies of new and established drugs, including actionable recommendations and detailed case studies, and provide forecasts for future pricing scenarios in major markets.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 32

Pharmaceutical Pricing And Reimbursement: Strategies For Market Access Across The Us, Europe, Japan And Other Key Geographies

Table of Contents

Abstract